Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer's Trial

Annovis Bio Inc. (NYSE: ANVS) has achieved a critical milestone in its development of buntanetap for Alzheimer's disease, with all 84 U.S. clinical trial sites now fully activated and enrolling patients for the company's pivotal Phase 3 trial targeting early Alzheimer's disease. The activation of all sites represents a significant operational achievement that accelerates patient recruitment and brings the company closer to potentially delivering a new treatment option for the millions affected by this devastating neurodegenerative condition.

The clinical trial has reached an important inflection point, with the first group of participants having completed the 6-month treatment phase. This completion marks substantial progress in the study's timeline and maintains the company's schedule to deliver symptomatic data in the second half of 2026. According to CEO Maria Maccecchini, the study is now 25% complete, reflecting strong execution and continued momentum toward bringing buntanetap to patients in need of effective therapies.

The full activation of all clinical sites across the United States ensures broader patient access and geographic diversity in the trial population, which is crucial for generating robust data that can support regulatory approval. Most sites are already actively treating patients, indicating rapid enrollment progress following site activation. This operational efficiency is particularly important in Alzheimer's drug development, where previous trials have often faced challenges in patient recruitment and retention.

For the Alzheimer's community, this development represents hope for a potential new therapeutic approach. Current Alzheimer's treatments provide limited symptomatic relief but do not address the underlying neurodegeneration. The progression of Annovis Bio's trial brings closer the possibility of a treatment that could meaningfully impact disease progression and patient quality of life. The company's platform approach to neurodegenerative diseases suggests that success in Alzheimer's could have implications for other conditions, including Parkinson's disease.

The timing of this milestone is significant given the growing global burden of Alzheimer's disease and the limited treatment options currently available. With an aging population worldwide, effective Alzheimer's therapies represent both a critical medical need and substantial market opportunity. The company's progress positions it well in the competitive neurodegenerative disease treatment landscape, where successful drug development can transform patient care and create significant value.

For more information about Annovis Bio, visit https://www.annovisbio.com. Additional news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.